Evaluation and management of brain metastatic patients with high-risk gestational trophoblastic tumors
Evaluation and management of brain metastatic patients with high-risk gestational trophoblastic tumors
复制标题
DOI：
10.1111/j.1048-891x.2004.14536.x
复制
发表时间：
2004-09-01
影响因子：
4.8
通讯作者：
Hashemi, FA
中科院分区：
文献类型：
--
作者：
Ghaemmaghami, F;Behtash, N;Hashemi, FA
A retrospective study to evaluate the characteristics of brain metastatic patients with gestational trophoblastic tumors (GTT) and to analyze the results of treatment has been performed. During 1996-2001, 40 patients with metastatic GTT were diagnosed at Vali-e-Asr Hospital, Tehran, Iran. Of them, nine with brain metastases, which were documented with the help of computed tomography scan, were evaluated retrospectively. Eight patients received EMA-EP regimen (etoposide, methotrexate, actinomycin, etoposide, and cisplatinum) and one received EMA-CO (etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristin). All cases received whole brain irradiation therapy concurrently. The median age of the patients at diagnosis was 30 years (range: 17-53). Six of them were of early group (five with symptoms of central nervous system and one was detected during workup) and three were of late group (relapsed group). Five (56%) patients responded to treatment and four (44%) were deceased (three of them belonged to late group). It seems that multi-agent chemotherapy (EMA-EP) concurrently with whole brain irradiation results in acceptable survival rates in GTT patients with brain metastases.
